RA0803

antibody from Oursmab

Targeting: TSLP

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0803

Provider

Oursmab

Product name

Ecleralimab (Biosimilar Reference Antibody) (TSLP)

Antibody type

Monoclonal

Description

Ecleralimab developed by Novartis, is an investigational, inhaled antiasthmatic biologic therapy. Unlike most monoclonal antibodies, it is engineered as a monovalent Fab (antigen-binding fragment) antibody, a smaller format chosen for enhanced lung tissue penetration when delivered via inhalation. Its mechanism of action centers on being a potent and selective thymic stromal lymphopoietin (TSLP) inhibitor. By neutralizing TSLP in the airways, Ecleralimab aims to block a key upstream cytokine that initiates and drives multiple inflammatory pathways central to asthma pathophysiology.

Reactivity

Human

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.